Chronic Inflammatory Demyelinating Polyneuropathy
1. Lunn MPT, Manji H, Choudhary PP, et al., Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England, J Neurol Neurosurg Psychiatry, 1999;66:677–80.
2. McLeod JG, Pollard JD, Macaskill P, et al., Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia, Ann Neurol, 1999;46:910–3.
3. Chiò A, Cocito D, Bottacchi E, et al., Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy, J Neurol Neurosurg Psychiatry, 2007;78:1349–53.
4. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR, Chronic inflammatory demyelinating polyradiculoneuropathy. clinical characteristics, course, and recommendations for diagnostic criteria, Arch Neurol, 1989;46:878–84.
5. Dyck PJ, Prineas JW, Pollard JD, Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF (eds), Peripheral neuropathy, Philadelphia: WB Saunders Company, 1993;1498–517.
6. Bradley WG, Bennett RK, Good P, Little B, Proximal chronic inflammatory polyneuropathy with multifocal conduction block, Arch Neurol, 1988;45:451–5.
7. De Silva RN, Willison HJ, Doyle D, et al., Nerve root hypertrophy in chronic inflammatory demyelinating polyneuropathy, Muscle Nerve, 1994;17:168–70.
8. Katz JS, Saperstein DS, Gronseth G, et al., Distal acquired demyelinating symmetric neuropathy, Neurology, 2000;54:615.
9. Lewis RA, Sumner AJ, Brown MJ, Asbury AK, Multifocal demyelinating neuropathy with persistent conduction block, Neurology, 1982;32:958–64.
10. Midroni G, Dyck PJ, Chronic inflammatory demyelinating polyradiculoneuropathy: unusual clinical features and therapeutic responses, Neurology, 1996;46:1206–12.
11. Morgan GW, Barohn RJ, Bazan C III, et al., Nerve root enhancement with MRI in inflammatory demyelinating polyradiculoneuropathy, Neurology, 1993;43:618–20.
12. Mygland A, Monstad P, Chronic acquired demyelinating symmetric polyneuropathy classified by pattern of weakness, Arch Neurol, 2003;60:260–4.
13. Parry GJ, Clarke S, Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease, Muscle Nerve, 1988;11:103–7.
14. Saperstein DS, Amato AA, Wolfe GI, et al., Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome, Muscle Nerve, 1999;22:560–6.
15. Ruts L, van Koningsveld R, Van Doorn PA, Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations, Neurology, 2005;65:138–40.
16. Ruts L, Drenthen J, Jacobs BC, Van Doorn PA, Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study, Neurology, 2010;74:1680–6.
17. Van der Meché FGA, Vermeulen M, Busch HFM, Chronic inflammatory demyelinating polyneuropathy, Brain, 1989;112:1563–71.
18. Van Doorn PA, Vermeulen M, Brand A, et al., Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy, Arch Neurol, 1991;48:217–20.
19. Van den Berg PYK, Hadden RDM, Bouche P, et al., European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision, J Periph Nerv Syst, 2010;15:1–9.
20. van Schaik IN, Winer JB, de Haan R, Vermeulen M, Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review, Lancet Neurol, 2002;1:491–8.
21. Austin JH, Recurrent polyneuropathies and their corticosteroid treatment. With five-year observations of a placebo controlled case treated with corticophin, cortisone, and prednisone, Brain, 1958;81:157–92.
22. McCombe PA, Pollard JD, McLeod JG, Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases, Brain, 1987;110:1617–30.
23. Mehndiratta MM, Hughes RAC, Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy, Cochrane Database Syst Rev, 2002;(1):CD002062.
24. Bromberg MB, Carter O, Corticosteroid use in the treatment of neuromuscular disorders: empirical and evidence-based data, Muscle Nerve, 2004;30:20–37.
25. Dalakas MC, Engel WK, Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment, Ann Neurol, 1981;9:134–5.
26. Dyck PJ, O’Brien P, Oviatt KF, Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment, Ann Neurol, 1982;11:136–41.
27. Hughes RA, Bensa S, Willison HJ, et al., Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy, Ann Neurol, 2001;50:195–201.
28. van Schaik IN, Eftimov F, Van Doorn PA, et al., Pulsed high dose dexamethasone treatment versus standard prednisolone treatment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a double-blind randomised controlled clinical trial (PREDICT study), Lancet Neurol, 2010;9:245–53.
50
29. Lopate G, Pestronk A, Al-Lozi M, Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone, Arch Neurol, 2005;62:249–54.
30. Molenaar DSM, Van Doorn PA, Vermeulen M, Pulse high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study, J Neurol Neurosurg Psychiatry, 1997;62:388–90.
31. Muley SA, Kelkar P, Parry GJ, Treatment of chronic inflammatory demyelinating polyneuropathy with pulsed oral steroids, Arch Neurol, 2008;65:1460–4.
32. Cheng Y, Wong RSM, Soo YOY, et al., Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone, N Engl J Med, 2003;349:831–6.
33. Vermeulen M, Van der Meché FGA, Speelman JD, et al., Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy, J Neurol Sci, 1985;70:317–26.
34. Faed JM, Day B, Pollock M, et al., High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy, Neurology, 1989;39:422–5.
35. Van Doorn PA, Rossi F, Brand A, et al., On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy, J Neuroimmunol, 1990;29:57–64.
36. Van Doorn PA, Brand A, Strengers PFW, et al., High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study, Neurology, 1990;40:209–12.
37. Cornblath DR, Chaudhry V, Griffin JW, Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin, Ann Neurol, 1991;30:104–6.
38. Jacob S, Rajabally YA, Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies, Curr Neuropharmacol, 2009;7:337–42.
39. Kazatchkine MD, Kaveri SV, Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin, N Engl J Med, 2001;345:747–55.
40. Yu Z, Lennon VA, Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases, N Engl J Med, 1999;340:227–8.
41. van Schaik IN, Vermeulen M, Brand A, In vitro effects of polyvalent immunoglobulin for intravenous use, J Neurol Neurosurg Psychiatry, 1994;57:S15–S17.
42. van Schaik IN, Lundkvist I, Vermeulen M, Brand A, Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro, J Clin Immunol, 1992;12:1–10.
43. Eftimov F, Winer JB, Vermeulen M, et al., Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy, Cochrane Database Syst Rev, 2009;(1):CD001797.
44. Vermeulen M, Van Doorn PA, Brand A, et al., Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy, J Neurol Neurosurg Psychiatry, 1993;56:36–9.
45. Hahn AF, Bolton CF, Zochodne DW, Feasby TE, Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study, Brain, 1996;119:1067–77.
46. Mendell JR, Barohn RJ, Freimer ML,et al., Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy, Neurology, 2001;56:445–9.
47. Thompson N, Choudhary PP, Hughes RAC, Quinlivan RM, A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy, J Neurol, 1996;243:280–5.
48. Hughes RA, Donofrio P, Bril V, et al., Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo- controlled trial, Lancet Neurol, 2008;7:136–44.
49. Dyck PJ, Litchy WJ, Kratz KM, et al., A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy, Ann Neurol, 1994;36:838–45.
50. Van Doorn PA, Dippel DWJ, Vermeulen M, Longterm iv immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy, J Periph Nerv Syst, 2007;12 (Suppl.):89.
51. Sekul EA, Cupler EJ, Dalakas MC, Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors, Ann Intern Med, 1994;121:259–62.
52. Debes A, Bauer M, Kremer S, Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study, Pharmacoepidemiol Drug Saf, 2007;16:1038–47.
53. Martin TD, Safety and tolerability of intravenous immunoglobulins. In: Said G (ed.), Treatment of Neurological Disorders with Intravenous Immunoglobulins, London: Martin Duntiz, 2000;181–91.
54. Duhem C, Dicato MA, Ries F, Side-effects of intravenous immune globulins, Clin Exp Immunol, 1994;97(Suppl. 1):79–83.
55. Dalakas MC, Clark WM, Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record, Neurology, 2003;60:1736.
56. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr, The clinical features of 16 cases of stroke associated with
administration of IVIg, Neurology, 2003;60:1822.
57. Brettle RP, Gross M, Legg NJ, et al., Treatment of acute polyneuropathy by plasma exchange, Lancet, 1978;2:1100.
58. Server AC, Lefkowith J, Braine H, McKhann GM, Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange, Ann Neurol, 1979;6:258–61.
59. Mehndiratta MM, Hughes RAC, Agarwal P, Plasma exchange for chronic inflammatory demyelinating polyradiculopathy, Cochrane Database Syst Rev, 2004;3:CD003906.
60. Levy RL, Newkirk R, Ochoa J, Treating chronic relapsing Guillain-Barre syndrome by plasma exchange, Lancet, 1979;2:259–60.
61. Dyck PJ, Daube J, O’Brien P, et al., Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy, N Engl J Med, 1986;314:461–5.
62. Hahn AF, Bolton CF, Pillay N, et al., Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropath: a double-blind, sham-controlled, cross-over study, Brain, 1996;119:1055–66.
63. Isose S, Mori M, Misawa S, et al., Long-term regular plasmapheresis as a maintenance treatment for chronic inflammatory demyelinating polyneuropathy, J Periph Nerv Syst, 2010;15:147–9.
64. Zinman LH, Sutton D, Ng E, et al., A pilot study to compare the use of the Excorim staphylococcal protein immunoadsorption system and IVIg in chronic inflammatory demyelinating polyneuropathy, Transfus Apher Sci, 2005;33:317–24.
65. Norda R, Stegmayr BG, Therapeutic apheresis in Sweden: update of epidemiology and adverse events, Transfus Apher Sci, 2003;29:159–66.
66. Kiprov DD, Golden P, Rohe R, et al., Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures, J Clin Apher, 2001;16:130–3.
67. Hughes RAC, Swan A, Van Doorn PA, Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculopathy, Cochrane Database Syst Rev, 2004;4:CD003280.
68. Dyck PJ, O’Brien P, Swanson C, et al., Combined azathioprine and prednisone in chronic inflammatory demyelinating polyneuropathy, Neurology, 1985;35:1173–6.
69. Fialho D, Chan YC, Allen DC, et al., Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate, J Neurol Neurosurg Psychiatry, 2006;77:544–7.
70. RMC Trial Group, Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study, Lancet Neurol, 2009;8:158–64.
71. Diaz-Manera J, Rojas-Garcia R, Gallardo E, Illa I, Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient, Muscle Nerve, 2010;39:386–8.
72. Yazici Y, Sokka T, Kautiainen H, et al., Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities, Ann Rheum Dis, 2005;64:207–11.
73. Mowzoon N, Sussman A, Bradley WG, Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis, J Neurol Sci, 2001;185:119–22.
74. Radziwill AJ, Schweikert K, Kuntzer T, et al., Mycophenolate mofetil for chronic inflammatory demyelinating polyradiculoneuropathy, Eur Neurol, 2006;56:37–8.
75. Chaudhry V, Cornblath DR, Griffin JW, et al., |Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases, Neurology, 2001;56:94–6.
76. Umapathi T, Hughes RA, Mycophenolate in treatment-resistant inflammatory neuropathies, Eur J Neurol, 2002;9:683–5.
77. Benedetti L, Grandis M, Nobbio L, et al., Mycophenolate mofetil in dysimmune neuropathies: a preliminary study, Muscle Nerve, 2004;29:748–9.
78. Gorson KC, Amato AA, Ropper AH, Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy, Neurology, 2004;63:715–7.
79. Bedi G, Brown A, Tong T, Sharma KR, Chronic inflammatory demyelinating polyneuropathy responsive to mycophenolate mofetil therapy, J Neurol Neurosurg Psychiatry, 2010;81:634–6.
80. Prineas JW, McLeod JG, Chronic relapsing polyneuritis, J Neurol Sci, 1976;27:427–58.
81. Brannagan TH, III, Pradhan A, Heiman-Patterson T, et al., High-dose cyclophosphamide without stem-cell rescue for refractory CIDP, Neurology, 2002;58:1856–8.
82. Good JL, Chehrenama M, Mayer RF, Koski CL, Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy, Neurology, 1998;51:1735–8.
83. Axelson HW, Oberg G, Askmark H, Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP, J Neurol Neurosurg Psychiatry, 2008;79:612–4.
84. Barnett MH, Pollard JD, Davies L, McLeod JG, Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy, Muscle Nerve, 1998;21:454–60.
85. Matsuda M, Hoshi K, Gono T, et al., Cyclosporin A in treatment of refractory patients with chronic inflammatory demyelinating polyradiculoneuropathy, J Neurol Sci, 2004;224:29–35.
86. Odaka M, Tatsumoto M, Susuki K, et al., Intractable CIDP treated succesfully with ciclosporin, J Neurol Neurosurg Psychiatry, 2005;76:1115–20.
EUROPEAN NEUROLOGICAL REVIEW
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76